| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 (NCT05105048) | ModernaTX, Inc. | 2021-11-08 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age (NCT05085366) | ModernaTX, Inc. | 2021-10-26 |
| A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection (NCT04706923) | SymBio Pharmaceuticals | 2021-08-16 |
| A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine (NCT04975893) | ModernaTX, Inc. | 2021-06-18 |
| Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults (NCT04232280) | ModernaTX, Inc. | 2020-01-09 |
| MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) (NCT04129398) | Merck Sharp & Dohme LLC | 2019-12-27 |
| Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) (NCT03930615) | Merck Sharp & Dohme LLC | 2019-06-21 |
| Dried Blood Spot Testing of CMV Detection in HCT Recipients (NCT03910478) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-05-03 |
| Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults (NCT03382405) | ModernaTX, Inc. | 2017-11-13 |
| Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation (NCT02702427) | St. Anna Kinderkrebsforschung | 2016-08-03 |
| Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV (NCT02798692) | Hookipa Biotech GmbH | 2016-06-01 |
| Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients (NCT03210090) | Maimónides Biomedical Research Institute of Córdoba | 2016-01-01 |
| Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers (NCT02454699) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-11-10 |
| Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss (NCT01649869) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-02-24 |
| Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients (NCT02156479) | Lophius Biosciences GmbH | 2014-07-01 |
| Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A (NCT02328963) | University Hospital, Bordeaux | 2014-05-02 |
| Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus (NCT01941056) | City of Hope Medical Center | 2014-01-05 |
| An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients (NCT02103426) | Astellas Pharma Global Development, Inc. | 2013-12-30 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") (NCT01552369) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-10-29 |
| Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate (NCT01354301) | Hospital do Rim e Hipertensão | 2011-05-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Alternate Donor Study of Pre-Emptive Cellular Therapy (NCT01220895) | Cell Medica Ltd | 2010-10-01 |
| Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants (NCT01178905) | University Hospital Tuebingen | 2010-08-01 |
| Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients (NCT01473849) | Sociedad Española de Trasplante Hepático | 2010-05-01 |
| Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients (NCT00942305) | Jazz Pharmaceuticals | 2009-10-01 |
| In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir (NCT01037712) | Assistance Publique - Hôpitaux de Paris | 2009-09-01 |
| Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection (NCT00881517) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2009-06-01 |
| Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus (NCT00880789) | Baylor College of Medicine | 2009-05-01 |
| Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy (NCT00966836) | University of Bologna | 2009-04-01 |
| Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study (NCT01077908) | Cell Medica Ltd | 2008-07-01 |
| Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections (NCT00466817) | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-06-01 |
| Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients (NCT00817908) | University of Alberta | 2008-05-01 |
| Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients (NCT00699868) | Assistance Publique Hopitaux De Marseille | 2008-03-01 |
| Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge (NCT00373412) | University of California, San Francisco | 2006-10-01 |
| Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM (NCT00370006) | University of California, San Francisco | 2006-09-01 |
| Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection (NCT00400322) | Karolinska Institutet | 2006-08-01 |
| TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant (NCT00386412) | PETHEMA Foundation | 2005-11-01 |
| A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients. (NCT00273143) | Mayo Clinic | 2005-05-01 |
| Maribavir for Prevention of CMV After Stem Cell Transplants (NCT00223925) | Shire | 2004-10-28 |
| Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients (NCT00730769) | Salvador Gil-Vernet | 2004-03-01 |
| Cytomegalovirus (CMV) Infection in Pregnancy (NCT00194155) | University of Pennsylvania | 2003-05-01 |
| Study of Prophylactic Vs Preemptive Valganciclovir (NCT00374686) | Washington University School of Medicine | 2003-03-01 |
| Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts (NCT00023036) | National Institute on Deafness and Other Communication Disorders (NIDCD) | 2001-09-04 |
| Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients (NCT00373165) | Lower Saxony Center for Nephrology | 2000-08-01 |
| Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection (NCT00001976) | National Institute of Allergy and Infectious Diseases (NIAID) | 2000-01-01 |